1 Original Article

2

3 Early Reduction of SARS-CoV-2 Replication in Bronchial Epithelium by

- 4 Kinin B₂ Receptor Antagonism
- 5 Short title: B₂R Antagonist Suppresses SARS-CoV-2 Replication
- 6
- 7 Constanze A. Jakwerth^{1*}, Martin Feuerherd^{2*}, Ferdinand M. Guerth¹, Madlen Oelsner¹, Linda
- 8 Schellhammer³, Johanna Giglberger^{1,6}, Lisa Pechtold⁶, Claudia Jerin^{1,6}, Luisa Kugler⁶, Carolin
- 9 Mogler⁴, Bernhard Haller⁵, Anna Erb¹, Barbara Wollenberg⁶, Christoph D. Spinner⁷, Thorsten
- 10 Buch³, Ulrike Protzer², Carsten B. Schmidt-Weber^{1,§}, Ulrich M. Zissler^{1#}, Adam M. Chaker^{1,6#}
- 11
- 12 1) Center of Allergy & Environment (ZAUM), Technical University of Munich and Helmholtz
- 13 Center Munich, German Research Center for Environmental Health, Member of the German
- 14 Center for Lung Research (DZL), CPC-M, Munich, Germany
- 15 2) Institute of Virology, Technical University of Munich/Helmholtz Zentrum München,
- Munich, Germany; German Center of Infectiology Research (DZIF), Munich partner site,
 Munich, Germany
- 18 3) Institute of Laboratory Animal Science, University of Zurich, Zurich, Switzerland
- 19 4) Institute of Pathology, Technical University Munich, Munich, Germany
- 5) Institute of Medical Informatics, Statistics and Epidemiology, Medical School, TechnicalUniversity of Munich
- 6) Department of Otorhinolaryngology and Head and Neck Surgery, Medical School, Technical
- 23 University of Munich, Germany
- 24 7) Department of Internal Medicine II, University Hospital rechts der Isar, Medical School,
- 25 Technical University of Munich, Munich, Germany
- 26 *) These authors contributed equally
- 27 *#*) These senior authors contributed equally
- 28
- 29 §) Corresponding author:
- 30 Prof. Dr. Carsten B. Schmidt-Weber, Chair & Director
- 31 Center of Allergy & Environment (ZAUM)
- 32 Technical University and Helmholtz Center Munich
- **33** Biedersteiner Str. 29
- 34 80202 Munich, Germany
- 35 Email: <u>csweber@tum.de</u>
- 36 Note: This 40080 rad and be used to guide clinical practice.
- 37

38 Conflict of interests:

39 Dr. Jakwerth reports grants from Federal Ministry of Education and Research, grants from 40 European Institute of Innovation & Technology (EIT), during the conduct of the study. Mr. 41 Feuerherd reports personal fees from Helmholtz Zentrum München and Dr. Höhnle AG, outside 42 the submitted work. Dr. Spinner reports grants, personal fees, non-financial support and other 43 from AbbVie, grants, personal fees, non-financial support and other from Apeiron, personal 44 fees from Formycon, grants, personal fees, non-financial support and other from Gilead 45 Sciences, grants, personal fees and other from Eli Lilly, grants, personal fees, non-financial 46 support and other from Janssen-Cilag, grants, personal fees, non-financial support and other 47 from GSK/ViiV Healthcare, grants, personal fees, non-financial support and other from MSD, 48 outside the submitted work. Prof. Dr. Buch reports personal fees from Virometix AG, other 49 from Virometix AG, other from Trials24 GmbH, other from Clemedi AG, outside the submitted 50 work. Prof. Dr. Protzer reports grants from the Federal Ministry of Education and Research, the 51 German Center for Infection Research (DZIF), the German Research Foundation (DFG), the 52 European Union via Horizon 2020 and the Bavarian Research Foundation during conduct of 53 the study. She receives personal fees as an ad hoc scientific advisor from Abbvie, Arbutus, 54 Gilead, GSK, Johnson & Johnson, Vaccitech. Prof. Dr. Schmidt-Weber reports grants from 55 German Center for Lung Research (DZL), grants from Comprehensive Pulmonary Lung Center 56 (CPC) Munich during the conduct of the study. Personal Fees from Allergopharma and 57 Bencard, outside the submitted work. Dr. Zissler reports grants from Federal Ministry of 58 Education and Research, during the conduct of the study. Dr. Chaker reports grants for clinical 59 studies and research and other from Allergopharma, ALK Abello, AstraZeneca, Bencard / 60 Allergen Therapeutics, ASIT Biotech, Lofarma, GSK, Novartis, LETI, Inmunotek, Roche, 61 Sanofi Genzyme, Zeller and from the European Institute of Technology (EIT); has received 62 travel support from the European Academy of Allergy and Clinical Immunology (EAACI), 63 DGAKI, all outside the submitted work. In addition, Drs. Jakwerth, Feuerherd, Protzer,

64	Schmidt-Weber, Zissler and Chaker are named as inventors on the patent application 'Novel
65	approaches for treatment of SARS-CoV2-Infection in a patient'. Mr. Guerth, Ms. Oelsner, Dr.
66	Schellhammer, Ms. Giglberger, Ms. Pechtold, Dr. Jerin, Ms. Kugler, Dr. Mogler, Dr. Haller,
67	Ms. Erb, Prof. Dr. Wollenberg have nothing to disclose.
68	

Funding: This study was supported by funding from the German Center of Lung Research
(DZL), the Comprehensive Pneumology Center (CPC) Munich, the German Research
Foundation (DFG; 398577603, TR22), and the Federal Ministry of Education and Research
(ESCAPE; 01KI20169A).

73

74 Author contributions:

- 75 Study design A.M.C., C.S.W., U.P., C.A.J., M.F., U.M.Z., T.B.; collection of patient samples
- 76 A.M.C., J.G., L.P., Cl.J., L.K.; conduction of experiment C.A.J., M.F., F.G., M.O., C.M., L.S.,
- 77 J.G., L.K.; data collection C.A.J., M.F., F.G., M.O., U.M.Z., C.M., L.S., J.G., L.P., Cl.J., L.K.;
- 78 data analysis C.A.J., M.F., F.G., A.E., U.M.Z., C.M., B.H., L.S.; data interpretation A.M.C.,
- 79 C.S.W., U.P., C.A.J., M.F., U.M.Z., C.M., B.H., C.D.S., B.W., L.S., T.B.; literature search
- 80 A.M.C., C.S.W., C.A.J., M.F., U.M.Z., A.E.; writing all authors.
- 81
- 82

83 ABSTRACT (247/250 words)

Background: SARS-CoV2 has evolved to enter the host via the ACE2 receptor which is part
of the Kinin-kallirein pathway. This complex pathway is only poorly understood in context of
immune regulation but critical to control infection. This study examines SARS-CoV2 infection
and epithelial mechanisms of the kinin-kallikrein system at the kinin B₂ receptor level in SARSCoV-2 infection that is of direct translational relevance.

Methods: From acute SARS-CoV-2-positive patients and -negative controls, transcriptomes of
nasal brushings were analyzed. Primary airway epithelial cells (NHBEs) were infected with
SARS-CoV-2 and treated with the approved B₂R antagonist icatibant. SARS-CoV-2 RNA RTqPCR, cytotoxicity assays, plaque assays and transcriptome analyses were performed. The
treatment effect was further studied in a murine airway inflammation model *in vivo*.

94 Results: Here, we report a broad and strong upregulation of kallikreins and the kinin B₂ receptor 95 (B₂R) in the nasal mucosa of acutely symptomatic SARS-CoV-2-positive patients. A B₂R 96 antagonist impeded SARS-CoV-2 replication and spread in NHBEs, as determined in plaque 97 assays on Vero E6 cells. B₂R antagonism reduced the expression of SARS-CoV-2 entry 98 receptor ACE2 *in vitro* and in a murine airway inflammation model *in vivo*. In addition, it 99 suppressed gene expression broadly, particularly genes involved in G-protein-coupled-receptor 97 signaling and ion transport.

101 **Conclusions:** In summary, this study provides evidence that treatment with B₂R antagonists 102 protects airway epithelial cells from SARS-CoV-2 by inhibiting its replication and spread, 103 through the reduction of ACE2 levels and the interference with several cellular signaling 104 processes. Future clinical studies need to shed light on the airway protection potential of 105 approved B₂R antagonists, like icatibant, in the treatment of early-stage COVID-19.

106

107 Key words: ACE2; COVID-19; kinin B₂R antagonist; kinin-kallikrein system; SARS-CoV-2
108

109 Abbreviations:

110	ACE2	angiotensin-converting enzyme 2	
111	ant-B ₂ R	kinin B ₂ receptor antagonist	
112	BDKRB1	kinin B1 receptor (gene name)	
113	BDKRB2	kinin B ₂ receptor (gene name)	
114	B ₁ R	kinin B ₁ receptor	
115	B ₂ R	kinin B ₂ receptor	
116	B ₂ R antagonist	kinin B ₂ receptor antagonist	
117	CAS	contact activation system	
118	COVID-19	coronavirus disease of 2019	
119	DABK	des-Arg9-bradykinin	
120	GPCR	G protein-coupled receptor	
121	НС	hydrocortisone	
122	HMW-kininogen	high-molecular-weight-kininogen	
123	IC50	half maximal inhibitory concentration	
124	KKS	kinin-kallikrein system	
125	LDH	lactate dehydrogenase	
126	NHBE	normal human bronchial epithelial cells	
127	RAS	renin-angiotensin system	
128	SARS-CoV-2	Severe Acute Respiratory Syndrome Coronavirus-2	
129	TMPRSS	transmembrane serine protease	
130			

131 Word count: 3,476 / 3,500

132 1 INTRODUCTION

133 SARS-CoV-2 vaccines have been approved worldwide since the end of 2020 and are starting to show their protective effects in public health.^{1,2} Even with vaccines at hand, an important 134 135 medical need for therapeutic approaches for COVID-19 remains: Parts of the population refrain 136 from vaccination or are not eligible for it, immunocompromised individuals may not mount a 137 sufficient immune response after vaccination and escape variants, such as the currently 138 spreading SARS-CoV-2 variant Delta³, may breach the protection afforded by the vaccines.⁴⁻⁹ 139 Key factors for SARS-CoV-2 cell entry are two cell surface molecules, the angiotensin-140 converting enzyme 2 (ACE2) and the transmembrane serine protease (TMPRSS)2.¹⁰ TMPRSS2 141 cleaves the coronaviral spike protein and primes it for cell fusion, while ACE2 enables the virus 142 particle to enter the cell by binding of its spike protein.^{11,12} The latter acts as central component 143 in its function as terminal carboxypeptidase in the counter-regulatory axis of the reninangiotensin system (RAS) and the contact activation system (CAS),^{10,13} which initiates blood 144 145 coagulation and can additionally activate the kinin-kallikrein system (KKS).¹⁴ In its role in the 146 RAS, ACE2 has anti-vasoconstrictive and anti-inflammatory effects by hydrolyzing the 147 vasoconstrictive and tissue-damaging angiotensin II, which contributes to airway remodeling and fibrosis,^{15,16} to angiotensin (1-7).¹⁷ In its role in the KKS, ACE2 further hydrolyzes 148 149 vasoactive peptides such as des-Arg9-bradykinin (DABK), which activates the inflammatory 150 axis of the KKS.^{18,19} While DABK is the ligand of the inducible kinin B₁ receptor (*BDKRB1*; 151 B₁ receptor),²⁰ bradykinin, the end product of the KKS cascade, binds to the constitutively expressed kinin B2 receptor (BDKRB2; B2 receptor; B2R) and activates it.²¹ Bradykinin 152 153 mediates its pro-inflammatory effects via the B₂ receptor, by eliciting a variety of responses, 154 including vasodilation and edema, via the G protein-triggered phosphatidylinositol-calcium second messenger system.²²⁻²⁶ 155

The fact that SARS-CoV-2 utilizes ACE2 to enter airway cells along with the fact that ACE2
is a multifunctional enzyme that counter-regulates the ACE-driven mechanisms of the RAS and
balances the KKS, may therefore explain the serious course of COVID-19, not only in the lungs
but systemically.^{27,28}
Recent publications suggest that the KKS could play a role in COVID-19. KKS comes into play

particularly in connection with the high prevalence of thromboembolic events in seriously ill COVID-19 patients.^{7,18,20,29,30} A recent study on a cohort of 66 COVID-19 patients admitted to the intensive care unit showed that the KKS was strongly activated, which was reflected in the consumption of factor XII, pre-kallikrein and high-molecular-weight kininogen (HMWkininogen).²⁹ It has further been hypothesized that kinin-dependent "local lung angioedema" involving the kinin B₁ and B₂ receptors is an important characteristic of COVID-19.³¹⁻³⁴

167 This study examines the potential of interfering with the KKS at the kinin receptor level in 168 SARS-CoV-2 infection with translational relevance. Based on a broad and strong upregulation 169 of kallikreins and of the kinin B₂ receptor in the nasal mucosa of acutely SARS-CoV-2-positive 170 patients, we hypothesized that the B₂ receptor antagonism using icatibant, an approved 171 compound for the treatment of hereditary angioedema,³⁵ had an early protective effect against 172 SARS-CoV-2-mediated epithelial damage through disruption of ACE2-mediated virus entry.

174 2 MATERIALS AND METHODS

175 2.1 Patients and nasal brushings

The nasal brushings were performed as a part of a larger health professional observational cohort study, which was approved by the ethics commission of the Technical University of Munich (AZ 175/20s). Nasal brushings were subjected to whole-genome microarray transcriptome analysis (see Supp.Info.). All patients gave written, informed consent prior to participation (see Table 1).

181

182 2.2 In vivo mouse study

183 Mice received murine IL-12Fc (1 µg of protein in 50 µL PBS) or PBS control intranasally.³⁶ 184 Intranasal application was performed under isoflurane anesthesia in two steps of 25 µL per 185 nostril. 48 hours later, the mice received a single subcutaneous injection of icatibant (2 nmol 186 per 10 g body weight; HOE-140 (icatibant), H157, SLBX4410, Sigma) or PBS control. The 187 experiment was terminated by CO₂ asphysiation 6 hours or 24 hours after the injection of 188 icatibant. The experiment was carried out twice Organs were snap frozen for protein extraction. 189 Mice enrolled in the experiment were 6-8 weeks old, from either C57BL/6J, BALB/c or C3H 190 HeN strains. Both sexes were included for each strain and means of each mouse type (strain / 191 sex) are depicted as single values in Fig.2A: circle: female; triangle: male. Black: C57BL/6, 192 mid grey: C3H HeN, light grey: BALB/c strain. Experiments were performed and analyzed in 193 a randomized and blinded fashion. Animals were obtained from Janvier Labs (Le Genest-Saint-194 Isle, France) and housed 5 per cage and sex in individually ventilated cages at Laboratory 195 Animal Service Center of the University of Zurich in Schlieren (Schlieren, Zurich, 196 Switzerland). The animal vivarium was a specific-pathogen-free (SPF) holding room, that was 197 temperature- and humidity-controlled $(21 \pm 3 \text{ °C}, 50 \pm 10\%)$, with a 12h light/dark cycle. All 198 animals had ad libitum access to the same food and water throughout the entire study. All 199 procedures described in this study had previously been approved by the Cantonal Veterinarian's

- 200 Office of Zurich, Switzerland (License ZH096/20), and every effort was made to minimize the
- 201 number of animals used and their suffering. Experiments were pre-registered at
- 202 www.animalstudyregistry.org (study title "Effect of drug on ACE2 levels in mice";
- doi=10.17590/asr.0000225).
- 204 Detailed methods are provided in the online supporting information.

206 3 RESULTS

207 3.1 B₂ receptor antagonist inhibits replication and spread of SARS-CoV-2

The enzyme ACE2 is the central viral entry receptor for the novel SARS-CoV-2 coronavirus on human epithelial cells of the respiratory tract.¹⁰ Recent studies showed that this receptor and its co-receptors are not only expressed in the lower respiratory tract, and thus on the alveolar epithelial cells type I and II, but are also present in the upper respiratory tract, but are predominantly expressed in the nasal mucosa.³⁷

213 To investigate the local effect of the acute SARS-CoV-2 infection on the nasal epithelium, we 214 analyzed the transcriptome of nasal brushings from symptomatic patients who tested acutely 215 positive for SARS-CoV-2 and of SARS-CoV-2-negative patients. In a transcriptome analysis, 216 the most strongly induced genes encoding secreted factors included many members of the 217 kallikrein family (Fig.1A, Table S1). In particular, the kallikreins KLK5, KLK9 and KLK12 218 were significantly upregulated in acute SARS-CoV-2-positive patients compared to SARS-219 CoV-2-negative patients (Fig.1B, Table S2). A subsequent analysis focusing on central factors 220 of the KKS revealed that in addition, the kinin receptor B₂ (BDKRB2; B₂R) was also 221 significantly increased (Fig.1C, Table S3). This first finding, together with our hypothesis that 222 ACE2, as a central component, is counter-regulated by intervention in the KKS, prompted us 223 to investigate selective kinin B₂ receptor antagonism in connection with SARS-CoV-2 224 infection. To circumvent the limitations of cell lines like Vero E6, A549 or Calu-3 cells that are 225 intrinsically impaired to form an interferon response upon viral infection,³⁸ we next infected 226 primary bronchial epithelial (NHBE) cells with SARS-CoV-2.

To examine the effects of SARS-CoV-2 infection and B₂R antagonist treatment on the microscopic integrity of the airway epithelium, 3D-air-liquid interphase organoid cultures were differentiated from primary NHBEs (see Supp.Info). After complete differentiation, the epithelia were pre-treated from the basal (medium) side with the approved B₂R antagonist icatibant, and subsequently infected with SARS-CoV-2 from the apical (air) side. The cultures

232 pre-treated with the B₂R antagonist showed less virus-induced balloon-like structures compared 233 to untreated cultures. The epithelial layers remained qualitatively more intact, which indicated 234 a protective effect of the B₂R antagonist for the bronchial epithelium (Fig.1D). This finding was further strengthened by cytotoxicity assays: The B2R antagonist had no toxic effects on 235 236 NHBEs even at high doses determined by lactate dehydrogenase (LDH) release, but rather 237 exhibited a cell-protecting effect in uninfected cells (Fig.1E) as well as during SARS-CoV-2 238 infection (Fig.1F). Next, the supernatants of pre-treated, infected primary NHBEs were 239 collected, titrated onto fresh Vero E6 cell cultures and plaque assays were performed. 240 Strikingly, we found that in vitro treatment of NHBEs with the B₂R antagonist prior to infection reduced the number of plaque forming units (PFU) in a plaque assay by 87% (Fig.1G). In 241 242 addition, the levels of total SARS-CoV-2 RNA in cells that had been pretreated with the B₂R 243 antagonist decreased by 52% compared to untreated infected NHBEs (Fig.1H). With regard to 244 the virus entry process, ACE2 was reduced by pretreatment with the B₂R antagonist on the 245 mRNA level (Fig. 1I) and on the protein level (Fig. 1J). The membrane-standing protease 246 TMPRSS2 cleaves the spike protein for SARS-CoV-2 and primes it therefore for optimized 247 binding to its entry receptor ACE2. In contrast to ACE2, the TMPRSS2 transcript levels were 248 significantly increased in infected compared to uninfected NHBEs but were not affected by 249 B₂R antagonist pre-treatment (Fig.S2A). Further experiments on the effect of the B₂R 250 antagonist on the SARS-CoV-2 infection of NHBE showed that pre-treatment with the B₂R 251 antagonist significantly reduced infection-mediated cytotoxicity measured by LDH release 252 (Fig.1F).

253

3.2 Repetitive treatment with B₂R antagonist inhibits SARS-CoV-2 replication and spread post-infection

The finding that B₂R antagonism leads to a downregulation of ACE2 protein levels in lung
epithelial cells was confirmed *in vivo* in a murine airway inflammation model. 24 sex-matched

mice from three different strains per group were treated in two blocks intranasally with murine IL-12Fc to mimic virus-induced airway inflammation via activation of the IL-12 / IFN- γ axis.³⁶ After 48 hours, mice were injected subcutaneously (s.c.) with the B₂R antagonist and the experiment was terminated six hours or 24 hours later. IL-12Fc-pretreated mice, which were then further treated with the B₂R antagonist on day 2, had significantly reduced ACE2 protein levels in the lungs after six hours compared to control mice, which were only treated with PBS on day 2 (Fig.2A). This effect decreased after 24 hours.

Anticipating treatment of SARS-CoV-2 infected patients with the B₂R antagonist icatibant,

NHBEs were first infected with SARS-CoV-2 and then treated with the B₂R antagonist six
hours after infection. Confirming the results of the pre-treatment, post-infection treatment with
the B₂R antagonist also attenuated the cytopathic effect of SARS-CoV-2 (Fig.2B) and reduced

the number of PFU in a plaque assay on Vero E6 cells by 84% (Fig.2C).

270 We also aimed to reflect pharmacokinetics³⁹ during treatment of early infection by treating 271 NHBEs post-infection every 24 hours with the B₂R antagonist repeatedly for a period of 96 272 hours, reflecting the drug administration of this particular substance in real life. In cells treated 273 post-infection with 100 nM icatibant for 48 hours, the total viral RNA (Fig.2D-F IC₅₀(total 274 RNA 48h)=92.93; IC₅₀(total RNA 72h)=91.56) and also the genomic viral RNA (Fig.2G-I; 275 IC₅₀(total RNA 48h)=17.01; IC₅₀(total RNA 72h)=7.412) were significantly reduced by 49% and 42% on average, respectively. Treatment with 1000 nM icatibant for 48 hours led to a 276 277 reduction of the total SARS-CoV-2 RNA (Fig.2D-F) and also of the genomic SARS-CoV-2 278 RNA (Fig.2G-I) by 69% and 56% on average, respectively. The genomic viral RNA was 279 detected using RT-qPCR against the sequence of the SARS-CoV-2 RNA-dependent RNA 280 polymerase (*RdRP*), which is only found in virions as well as during the viral replication. On 281 the other hand, total viral RNA was detected with qPCR targeting a sequence of the SARS-282 CoV-2 N gene that is present in the viral genome and also in every SARS-CoV-2 protein-283 encoding transcript. The reduction in total SARS-CoV-2 RNA and genomic viral RNA during

treatment with the B₂R antagonist was comparable at the indicated concentrations and timepoints (Fig.2D-I).

286

3.3 B₂ receptor antagonism broadly silences gene expression in bronchial epithelial cells while maintaining cell-intrinsic antiviral response

Severe cases of COVID-19 develop cytokine storms⁴⁰⁻⁴² characterized by excessive systemic 289 290 release of multiple cytokines including IP-10 (CXCL10), IL-6, IL-8 (CXCL8), and IL-10.43-46 291 These cases are currently treated with immunomodulating drugs, such as corticosteroids or 292 biologics, like tocilizumab⁴⁷, though these treatments may interfere with or alter the antiviral 293 immune response. We therefore compared the effect of the B₂R antagonist on gene expression 294 of the bronchial epithelium in the light of SARS-CoV-2 infection with the effect of 295 hydrocortisone. While the B₂R antagonist mainly suppressed epithelial gene expression during 296 infection, the effects of hydrocortisone on gene induction and gene repression were equal (Fig.3A, Tables S4-5). This finding matches previous reports.⁴⁸ Therefore, conditions were 297 298 compared in respect to the antiviral epithelial response. In fact, differentially expressed genes 299 (DEGs) induced by SARS-CoV-2 infection in NHBEs encompassed type-I and -III interferons 300 as well as IFN-inducible and antiviral APOBEC genes (Fig.S1E, Table S6). In particular, 301 SARS-CoV-2 infection induced the antiviral cytidine deaminases APOBEC3A and B, which 302 we previously described to be induced by type-I interferons in the treatment of hepatitis-B virus 303 infection.⁴⁹ On the other hand, APOBEC3C mRNA levels were decreased in SARS-CoV-2-304 infected NHBE, which could indicate a novel evasion mechanism.⁵⁰ Neither the B₂R antagonist 305 nor hydrocortisone inhibited the expression of genes with cell-intrinsic antiviral effects and 306 even increased the antiviral factor APOBEC3A at the mRNA level (Fig.3B, Table S7).⁵¹ 307 Our gene expression analysis data show that SARS-CoV-2 infection also induces the expression 308 of acute-phase proteins, such as TNF- α and IL-8 (CXCL8),^{52,53} as well as IL-17C, MIP-

309 3α (*CCL20*), IL-36 $\gamma^{54,55}$ and the chemokines CXCL1, -2, -3, -8, -17, CCL2, -3, -5⁵⁴ in primary

310 lung epithelial cells (Fig.3C, Table S8). The induction of these factors most likely contributes 311 to the recruitment and activation of relevant immune cells to the site of infection. Our findings 312 are supported by previous studies of aberrant macrophage and T cell responses underlying 313 immunopathogenesis in bronchoalveolar lavage fluid from COVID-19 patients.⁵⁶ In addition, 314 the gene expression of acute-phase proteins was not significantly affected in airway epithelial 315 cells by the B₂R antagonist or hydrocortisone treatment (Fig.3C, Table S8). Neither drug 316 interfered with canonical cellular antiviral – and reaction-triggering response mechanisms, 317 showing great potential for treatment options of COVID-19 while maintaining the host's 318 antiviral immune response.

319 In addition, we found that SARS-CoV-2 infection increases the expression of three known and 320 postulated entry (co-)receptors: 1) the transmembrane serine protease TMPRSS11A (Fig.S1C, 321 Tables S6,9-13), which was described to prime the MERS coronavirus spike protein⁵⁷, 2) the 322 transmembrane serine protease TMPRSS11D, which was shown to activate SARS-CoV-2 spike 323 protein⁵⁸ and 3) the pathogen-associated molecular pattern-binding C-type lectin receptor DC-324 SIGN (CD209), which was described to serve as entry receptor for SARS-CoV⁵⁹ and has been 325 suggested to act as a receptor also for SARS-CoV-2. The induction of these additional entry 326 receptor candidates triggered by SARS-CoV-2 infection may potentiate the viral spread in the 327 bronchial epithelium and thus represent a pathogenetic approach that needs further research.

328 Overall, treatment with the B₂R antagonist and hydrocortisone had no significant effects on the 329 expression of these candidate viral entry receptors (Fig.3D, Table S14). On the other hand, 330 hydrocortisone enhanced the expression of TMPRSS proteases (Fig.3D). In particular, when 331 focusing on the known SARS-CoV-2 entry receptors, hydrocortisone treatment of uninfected 332 cells was already sufficient to induce an increase in TMPRSS2 gene expression (Fig.3E). SARS-333 CoV-2 infection per se also increased TMPRSS2 expression, and pre-treatment of SARS-CoV-334 2-infected NHBEs with hydrocortisone further potentiated this effect. On the other hand, ACE2 335 expression showed only a slight upward trend after hydrocortisone pretreatment (Fig.S2B).

Finally, the hydrocortisone pre-treatment of SARS-CoV-2-infected NHBEs had no inhibitory effect on the release of infectious particles 24 hours after infection (Fig.3F), which was expected since the treatment of COVID-19 patients with corticosteroids has an immunomodulatory rationale.

340

341 3.4 B₂ receptor antagonist counter-balances virus-induced gene expression, particularly 342 genes involved in G protein-coupled receptor (GPCR) signaling and ion transport

343 With regard to the genes that are attenuated at the mRNA level by B₂R antagonism, the DEGs 344 were analyzed in a network analysis using the database string to identify enriched cellular 345 processes. B₂R antagonism reduced the expression levels of 343 membrane-bound receptors 346 significantly in treated versus untreated SARS-CoV-2-infected NHBEs (Table S15). Two 347 particular cellular processes affected by pre-treatment with the B₂R antagonist were identified, 348 namely G protein-coupled receptor signaling (GO:0007186; Fig.4A, S2C, Tables S4,S17-18) 349 and ion transport (GO:0006811; Fig.4B, Tables S4,17-18). DEGs involved in both processes 350 were significantly downregulated in treated versus untreated SARS-CoV-2-infected NHBEs 351 (Tables 16-18). Notably, all 35 cell surface receptors induced by SARS-CoV-2 infection were 352 downregulated in cells that were treated with the B₂R antagonist (Fig.4C,D, Tables S19-20). 353

355 4 DISCUSSION

In this study, we provide evidence for the effect of interference with the KKS at the kinin B₂
receptor level as a means of protecting the airway epithelium from SARS-CoV-2 infection,
while maintaining canonical cell-intrinsic antiviral response.

359 We initially hypothesized that through KKS interference, either feedback mechanisms or 360 modulated signal transduction target the virus entry receptor ACE2 and thus interfere with the 361 spread of SARS-CoV-2. To this end, the approved B₂R antagonist icatibant was used in this 362 study. Here, we demonstrate that treatment with a B₂R antagonist inhibits the replication and 363 spread of SARS-CoV-2 in primary airway epithelial cells, which was determined by a decrease 364 in total and genomic SARS-CoV-2 RNA, resulting in less infectious particles in plaque assays, 365 both when applied pre- and post-infection. While a low concentration of 1 nM B₂R antagonist 366 was sufficient to reduce viral RNA in primary bronchial epithelial cells when cells were treated 367 pre-infection, 100 nM B₂R antagonist was required to this effect, when cells were treated post-368 infection. In addition, the significant reduction in virus load as determined by PCR tapered off 369 after 96 hours. On the one hand, in vitro infections are performed with excess amounts of virus 370 particles. On the other hand, the fact that, due to its constitution as a peptide analog, the B_2R antagonist icatibant used in this study has a short half-life in the human body³⁹ but also 371 372 pharmacological tolerance to interference at receptor level may explain why the effect reached 373 significance after six hours but did not persist. Therefore, a higher dose of the B₂R antagonist 374 may be required at even shorter repetitive dosing intervals to inhibit virus replication in the long 375 term. Therapeutic application in future dose finding studies should therefore focus on early intervention with at least two doses daily⁶⁰ and on either optimized pharmacokinetics or 376 377 increased high local tissue concentrations, e.g. through topical application.

378

379 Two potential mechanisms of action for suppressing SARS-CoV-2 replication and spread in380 airway epithelium are revealed by the current study:

1) Treatment with the B₂R antagonist led to a downregulation of the viral entry receptor ACE2, *in vitro* in primary airway epithelial cells and *in vivo* in a murine airway inflammation model. Since the decrease of genomic SARS-CoV-2 RNA and total SARS-CoV-2 RNA was comparable, we conclude that the B₂R antagonist icatibant does probably not affect the viral transcription machinery but inhibits the infection rather on the levels of entry, protein synthesis/processing and assembly, maturation or budding.

In comparison, the corticosteroid hydrocortisone even upregulated TMPRSS2 in infected airway epithelial cells. It is noteworthy that hydrocortisone did not change the release of infectious particles from infected airway epithelial cells into the supernatant. Although TMPRSS2 expression was even enhanced by hydrocortisone, our data implicate that this effect on TMPRSS2 alone is insufficient to increase susceptibility for SARS-CoV-2 infection.

392 2) Treatment with the B_2R antagonist had a broad suppressive effect on gene expression of

393 multiple cell signaling molecules, in particular on membrane-standing factors involved in394 GPCR signaling and ion transport.

395 It has recently been published that SARS-CoV-2 may use cellular GPCR signaling pathways, 396 thereby modulate epithelial transport mechanisms involved in ion transport and thereby cause a local ion imbalance in the airways.⁶¹ In addition, an extensive recent study described that 397 398 intracellular SARS-CoV-2 protein interactions include factors involved in intracellular 399 trafficking and transport, particularly ion transport and solute carrier transport.⁶² In fact, the 400 SARS-CoV-2 infection led to a differential regulation of the gene expression of 12 potassium 401 channel (5 upregulated / 7 downregulated), 1 sodium channel (down), but in particular of 55 402 members of the solute carrier family (24 downregulated / 31 upregulated) in primary airway 403 epithelial cells. On the other hand, B₂R antagonist treatment of SARS-CoV-2-infected NHBE 404 resulted in a downregulation of 20 potassium channel genes and 6 sodium channel genes, as well as a downregulation of 29 members of the solute carrier family. 405

We therefore conclude that B₂R antagonism not only impedes the viral entry process by reducing ACE2, as we had hypothesized, but also counter-regulates cellular processes that include GPCR signaling and transmembrane ion transport, which SARS-CoV-2 may utilize for efficient replication and viral spread.

410

411 In conclusion, the results of this study suggest that B₂ receptor-antagonism protects airway 412 epithelial cells from SARS-CoV-2 spread by reducing ACE2 levels and by interfering with 413 several cellular signaling processes. Further research is needed to elucidate more details about 414 molecular mechanisms involved in the viral life cycle that kinin B₂ receptor antagonism targets 415 and underlie its effects against SARS-CoV-2 infection. Based on these data, we speculate that 416 the protective effects of B₂R antagonism could potentially prevent the early stages of COVID-417 19 from progressing into severe acute respiratory distress syndrome (ARDS) with structural 418 airway damage and fibrotic changes. We therefore propose that the safe approved B₂R 419 antagonist icatibant be tested in clinical trials for two important aspects: 1) Treatment of early 420 COVID-19 disease targeting the replication and spread of the virus. 2) Optimized dosage 421 regimen to reflect pharmacokinetics and possible pharmacological tolerance at the receptor 422 level. Future controlled clinical trials must provide substantial evidence for optimal dosage 423 regimen, application, efficacy, and safety to investigate, whether KKS interference at the kinin 424 B₂ receptor level can prevent the escalation of COVID-19 to ARDS and long-term lung damage.

426 REFERENCES

- 427 1. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA 428 Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603-2615.
- 429 2. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with 430 SARS-CoV-2 in Wuhan, China. Allergy. 2020;75(7):1730-1741.
- 431 Planas D, Veyer D, Baidaliuk A, et al. Reduced sensitivity of SARS-CoV-2 variant 3. 432 Delta to antibody neutralization. Nature. 2021.
- 433 4. Hacisuleyman E, Hale C, Saito Y, et al. Vaccine Breakthrough Infections with SARS-434 CoV-2 Variants. N Engl J Med. 2021.
- 435 5. Schmidt F, Weisblum Y, Muecksch F, et al. Measuring SARS-CoV-2 neutralizing 436 antibody activity using pseudotyped and chimeric viruses. J Exp Med. 2020;217(11).
- 437 6. Sokolowska M, Lukasik ZM, Agache I, et al. Immunology of COVID-19: Mechanisms, 438 clinical outcome, diagnostics, and perspectives-A report of the European Academy of 439 Allergy and Clinical Immunology (EAACI). Allergy. 2020;75(10):2445-2476.
- 440 7. Gao YD, Ding M, Dong X, et al. Risk factors for severe and critically ill COVID-19 441 patients: A review. Allergy. 2021;76(2):428-455.
- 442 8. Bousquet J, Jutel M, Akdis CA, et al. ARIA-EAACI statement on asthma and COVID-443 19 (June 2, 2020). Allergy. 2021;76(3):689-697.
- 444 9. Du H, Dong X, Zhang JJ, et al. Clinical characteristics of 182 pediatric COVID-19 445 patients with different severities and allergic status. Allergy. 2021;76(2):510-532.
- 446 10. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends 447 on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 448 2020;181(2):271-280 e278.
- 449 11. Matsuyama S, Nagata N, Shirato K, Kawase M, Takeda M, Taguchi F. Efficient 450 activation of the severe acute respiratory syndrome coronavirus spike protein by the 451 transmembrane protease TMPRSS2. J Virol. 2010;84(24):12658-12664.
- 452 Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional 12. 453 receptor for the SARS coronavirus. Nature. 2003;426(6965):450-454.
- 454 13. Diamond B. The renin-angiotensin system: An integrated view of lung disease and 455 coagulopathy in COVID-19 and therapeutic implications. J Exp Med. 2020;217(8).
- 456 14. Schmaier AH. The contact activation and kallikrein/kinin systems: pathophysiologic 457 and physiologic activities. J Thromb Haemost. 2016;14(1):28-39.
- 458 15. Stukalov A, Girault V, Grass V, et al. Multilevel proteomics reveals host perturbations 459 by SARS-CoV-2 and SARS-CoV. Nature. 2021.
- 460 16. Imai Y, Kuba K, Rao S, et al. Angiotensin-converting enzyme 2 protects from severe 461 acute lung failure. Nature. 2005;436(7047):112-116.
- 462 17. Santos RAS, Sampaio WO, Alzamora AC, et al. The ACE2/Angiotensin-(1-7)/MAS 463 Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7). Physiol Rev. 464 2018;98(1):505-553.
- 465 18. Meini S, Zanichelli A, Sbrojavacca R, et al. Understanding the Pathophysiology of 466 COVID-19: Could the Contact System Be the Key? Front Immunol. 2020;11:2014.
- 467 19. Vickers C, Hales P, Kaushik V, et al. Hydrolysis of biological peptides by human 468 angiotensin-converting enzyme-related carboxypeptidase. JBiol Chem. 469 2002;277(17):14838-14843.
- 470 van de Veerdonk FL, Netea MG, van Deuren M, et al. Kallikrein-kinin blockade in 20. 471 patients with COVID-19 to prevent acute respiratory distress syndrome. *Elife*. 2020;9.
- 472 21. Shen B, Harrison-Bernard LM, Fuller AJ, Vanderpool V, Saifudeen Z, El-Dahr SS. The 473 Bradykinin B2 receptor gene is a target of angiotensin II type 1 receptor signaling. JAm 474 Soc Nephrol. 2007;18(4):1140-1149.

medRxiv preprint doi: https://doi.org/10.1101/2021.08.13.21262037; this version posted August 18, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. All rights reserved. No reuse allowed without permission.

- 475 22. Burch RM, Axelrod J. Dissociation of bradykinin-induced prostaglandin formation 476 from phosphatidylinositol turnover in Swiss 3T3 fibroblasts: evidence for G protein 477 regulation of phospholipase A2. Proc Natl Acad Sci USA. 1987;84(18):6374-6378.
- 478 Slivka SR, Insel PA. Phorbol ester and neomycin dissociate bradykinin receptor-23. 479 mediated arachidonic acid release and polyphosphoinositide hydrolysis in Madin-Darby 480 canine kidney cells. Evidence that bradykinin mediates noninterdependent activation of 481 phospholipases A2 and C. J Biol Chem. 1988;263(29):14640-14647.
- 482 24. Yu HS, Lin TH, Tang CH. Involvement of intercellular adhesion molecule-1 up-483 regulation in bradykinin promotes cell motility in human prostate cancers. Int J Mol Sci. 484 2013;14(7):13329-13345.
- 485 25. Chen S, Zhang L, Xu R, et al. BDKRB2 +9/-9 bp polymorphisms influence BDKRB2 486 expression levels and NO production in knee osteoarthritis. Exp Biol Med (Maywood). 487 2017;242(4):422-428.
- 488 Souza PPC, Lundberg P, Lundgren I, Magalhaes FAC, Costa-Neto CM, Lerner UH. 26. 489 Activation of Toll-like receptor 2 induces B1 and B2 kinin receptors in human gingival 490 fibroblasts and in mouse gingiva. Sci Rep. 2019;9(1):2973.
- 491 27. Imai Y, Kuba K, Penninger JM. The discovery of angiotensin-converting enzyme 2 and 492 its role in acute lung injury in mice. *Exp Physiol.* 2008;93(5):543-548.
- 493 28. Jia H. Pulmonary Angiotensin-Converting Enzyme 2 (ACE2) and Inflammatory Lung 494 Disease. Shock. 2016;46(3):239-248.
- 495 Lipcsey M, Persson B, Eriksson O, et al. The Outcome of Critically Ill COVID-19 29. 496 Patients Is Linked to Thromboinflammation Dominated by the Kallikrein/Kinin System. 497 Front Immunol. 2021;12:627579.
- 498 30. Mansour E, Palma AC, Ulaf RG, et al. Safety and Outcomes Associated with the 499 Pharmacological Inhibition of the Kinin-Kallikrein System in Severe COVID-19. 500 Viruses. 2021:13(2).
- 501 31. de Maat S, de Mast Q, Danser AHJ, van de Veerdonk FL, Maas C. Impaired Breakdown 502 of Bradykinin and Its Metabolites as a Possible Cause for Pulmonary Edema in COVID-503 19 Infection. Semin Thromb Hemost. 2020;46(7):835-837.
- 504 32. Garvin MR, Alvarez C, Miller JI, et al. A mechanistic model and therapeutic 505 interventions for COVID-19 involving a RAS-mediated bradykinin storm. Elife. 506 2020;9.
- 507 33. Kaplan AP, Ghebrehiwet B. Pathways for bradykinin formation and interrelationship 508 with complement as a cause of edematous lung in COVID-19 patients. J Allergy Clin 509 Immunol. 2021;147(2):507-509.
- Roche JA, Roche R. A hypothesized role for dysregulated bradykinin signaling in 510 34. 511 COVID-19 respiratory complications. FASEB J. 2020;34(6):7265-7269.
- 512 35. Bas M, Bier H, Greve J, Kojda G, Hoffmann TK. Novel pharmacotherapy of acute 513 hereditary angioedema with bradykinin B2-receptor antagonist icatibant. Allergy. 514 2006;61(12):1490-1492.
- 515 36. Eisenring M, vom Berg J, Kristiansen G, Saller E, Becher B. IL-12 initiates tumor 516 rejection via lymphoid tissue-inducer cells bearing the natural cytotoxicity receptor 517 NKp46. Nat Immunol. 2010;11(11):1030-1038.
- 518 37. Sungnak W, Huang N, Becavin C, et al. SARS-CoV-2 entry factors are highly expressed 519 in nasal epithelial cells together with innate immune genes. Nat Med. 2020;26(5):681-520 687.
- 521 Yoshikawa T, Hill TE, Yoshikawa N, et al. Dynamic innate immune responses of 38. 522 human bronchial epithelial cells to severe acute respiratory syndrome-associated 523 coronavirus infection. PLoS One. 2010;5(1):e8729.
- 524 39. Leach JK, Spencer K, Mascelli M, McCauley TG. Pharmacokinetics of single and 525 repeat doses of icatibant. Clin Pharmacol Drug Dev. 2015;4(2):105-111.

- 526 40. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel 527 coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.
- 528 41. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult 529 inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 530 2020;395(10229):1054-1062.
- 531 42. Burian E, Jungmann F, Kaissis GA, et al. Intensive Care Risk Estimation in COVID-19 532 Pneumonia Based on Clinical and Imaging Parameters: Experiences from the Munich Cohort. J Clin Med. 2020;9(5). 533
- 534 43. Zheng HY, Zhang M, Yang CX, et al. Elevated exhaustion levels and reduced functional 535 diversity of T cells in peripheral blood may predict severe progression in COVID-19 536 patients. Cell Mol Immunol. 2020.
- 537 44. Laing AG, Lorenc A, Del Molino Del Barrio I, et al. A dynamic COVID-19 immune 538 signature includes associations with poor prognosis. Nat Med. 2020;26(10):1623-1635.
- 539 45. Buszko M, Nita-Lazar A, Park JH, et al. Lessons learned: new insights on the role of 540 cytokines in COVID-19. Nat Immunol. 2021;22(4):404-411.
- 541 46. Azkur AK, Akdis M, Azkur D, et al. Immune response to SARS-CoV-2 and 542 mechanisms of immunopathological changes in COVID-19. Allergy. 2020;75(7):1564-543 1581.
- 544 47. Group RC. Tocilizumab in patients admitted to hospital with COVID-19 545 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 546 2021;397(10285):1637-1645.
- 547 48. Mostafa MM, Rider CF, Shah S, et al. Glucocorticoid-driven transcriptomes in human 548 airway epithelial cells: commonalities, differences and functional insight from cell lines and primary cells. BMC Med Genomics. 2019;12(1):29. 549
- 550 49. Lucifora J, Xia Y, Reisinger F, et al. Specific and nonhepatotoxic degradation of nuclear 551 hepatitis B virus cccDNA. Science. 2014;343(6176):1221-1228.
- 552 50. Milewska A, Kindler E, Vkovski P, et al. APOBEC3-mediated restriction of RNA virus 553 replication. Sci Rep. 2018;8(1):5960.
- 554 Wang Y, Schmitt K, Guo K, Santiago ML, Stephens EB. Role of the single deaminase 51. 555 domain APOBEC3A in virus restriction, retrotransposition, DNA damage and cancer. 556 J Gen Virol. 2016;97(1):1-17.
- 557 52. Rodgers HC, Pang L, Holland E, Corbett L, Range S, Knox AJ. Bradykinin increases 558 IL-8 generation in airway epithelial cells via COX-2-derived prostanoids. Am J Physiol 559 Lung Cell Mol Physiol. 2002;283(3):L612-618.
- 560 53. Norelli M, Camisa B, Barbiera G, et al. Monocyte-derived IL-1 and IL-6 are 561 differentially required for cytokine-release syndrome and neurotoxicity due to CAR T 562 cells. Nat Med. 2018;24(6):739-748.
- 563 54. Tay MZ, Poh CM, Renia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, 564 inflammation and intervention. Nat Rev Immunol. 2020.
- 565 55. Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role 566 for monocytes and macrophages. Nat Rev Immunol. 2020.
- 567 56. Mingfeng Liao YL, Jing Yuan, Yanling Wen, Gang Xu, Juanjuan Zhao, Lin Cheng, 568 Jinxiu Li, Xin Wang, Fuxiang Wang, Lei Liu, Ido Amit, Shuye Zhang & Zheng Zhang. 569 Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat 570 Med. 2020.
- 571 57. Zmora P, Hoffmann M, Kollmus H, et al. TMPRSS11A activates the influenza A virus 572 hemagglutinin and the MERS coronavirus spike protein and is insensitive against blockade by HAI-1. J Biol Chem. 2018;293(36):13863-13873. 573
- 574 Kishimoto M, Uemura K, Sanaki T, et al. TMPRSS11D and TMPRSS13 Activate the 58. 575 SARS-CoV-2 Spike Protein. Viruses. 2021;13(3).

- 576 59. Han DP, Lohani M, Cho MW. Specific asparagine-linked glycosylation sites are critical for DC-SIGN- and L-SIGN-mediated severe acute respiratory syndrome coronavirus 577 578 entry. J Virol. 2007;81(21):12029-12039.
- 579 van de Veerdonk FL, Kouijzer IJE, de Nooijer AH, et al. Outcomes Associated With 60. 580 Use of a Kinin B2 Receptor Antagonist Among Patients With COVID-19. JAMA Netw 581 Open. 2020;3(8):e2017708.
- 582 Abdel Hameid R, Cormet-Boyaka E, Kuebler WM, Uddin M, Berdiev BK. SARS-CoV-61. 583 2 may hijack GPCR signaling pathways to dysregulate lung ion and fluid transport. Am 584 J Physiol Lung Cell Mol Physiol. 2021;320(3):L430-L435.
- 585 62. Stukalov A, Girault V, Grass V, et al. Multilevel proteomics reveals host perturbations 586 by SARS-CoV-2 and SARS-CoV. Nature. 2021;594(7862):246-252.
- 587

588 FIGURE LEGENDS

Figure 1. Induction of kallikreins and kinin receptor B₂ in the nasal mucosa of acutely positive Covid-19 patients

591 A) Volcano plot of significantly differentially regulated genes (DEGs = differentially expressed 592 genes) in nasal brushings of patients that were acute positive for SARS-CoV-2 compared to 593 healthy individuals (negative) using human miR microarray technology. Highlighted genes 594 have a fold-change (FC)≥10 with P<0.05, genes in red are up-regulated, genes in blue are 595 downregulated. B) Heat map of gene expression analysis of kallikrein genes and C) of genes of 596 the kinin-kallikrein system (KKS) in nasal brushings comparing SARS-CoV-2 acute-positive 597 patients to healthy controls. All entities with $FC \ge 1.2$ are shown. Asterisks indicate significantly 598 regulated genes (P<0.05) in SARS-CoV-2-infected NHBEs compared to medium. Color code 599 indicates Log2-fold change from low (blue) through 0 (white) to high (red). Duplicate gene 600 names indicate the abundance of two or more isoforms of the same gene in the analysis. D) 3D-601 air-liquid interphase cultures from NHBEs were pre-treated for 24 hours with/without 1 nM 602 B₂R antagonist from the basal side and subsequently infected with SARS-CoV-2 for 48 hours 603 from the apical side.

604 E) Lactate dehydrogenase (LDH) cytotoxicity assay using the LDH Cytotoxicity Detection Kit 605 PLUS studying the effect of increasing doses of the B_2R antagonist after 48 hours in primary 606 NHBEs from 4 donors. Results are depicted as mean \pm s.e.m. Statistical tests compared each 607 dose of B_2R antagonist with 0 nM B_2R antagonist.

F) Cytotoxicity assay determining LDH release into the supernatants of cultures of SARS-CoV2-infected NHBEs from 12 donors that were pre-treated for 24 hours with/without 1 nM B₂R
antagonist.

G) Quantification of infectious particles in the supernatants of SARS-CoV-2-infected NHBEs
from 10 donors that were pre-treated with/without 1 nM B₂R antagonist for 24 hours.
Supernatants were titrated on Vero E6 cells and plaque assay was quantified 24 hours later.

614 Results are depicted as plaque forming units (PFU) per milliliter.

- 615 H) qPCR analysis of total SARS-CoV-2 RNA (viral genome and transcripts, which all contain
- 616 the N1 sequence region) normalized to human ACTB of SARS-CoV-2-infected primary NHBE
- 617 after 24 hours of pre-treatment with/without 1 nM B₂R antagonist followed by 24 hours of
- 618 SARS-CoV-2 inoculation. For Figures 1E, F, and H, statistical tests compared SARS-CoV-2-
- 619 infected versus uninfected samples or B₂R antagonist-treated versus untreated samples.
- 620 I) Analysis of human ACE2 gene expression using qPCR (n=10) and J) of human ACE2 protein
- 621 levels analyzed by ELISA from cell lysates (n=6) after 24 hours of pre-treatment of NHBEs
- 622 with/without 1 nM B₂R antagonist, followed by SARS-CoV-2 inoculation for 24 hours.
- 623

Figure 2. Treatment of NHBE with B₂R antagonist post-infection in repeated doses inhibits SARS-CoV-2 replication

626 A) In vivo mouse study. 12 sex-matched mice from three different strains per group were treated 627 on day 0 with intranasal application of 1 µg murine IL-12Fc per mouse or PBS as control to 628 mimic virus-induced airway inflammation. After 48h, mice were injected s.c. with 2 nmol of 629 the B₂R antagonist icatibant per 10 g of body weight or PBS as control. The experiment was 630 terminated either six hours or 24 hours later and murine lung ACE2 protein levels were 631 analyzed by mouse ACE2 ELISA analysis. Circle: female; triangle: male. Black: C57BL/6, mid 632 grey: C3H HeN, light grey: BALB/c strain. The experiment was carried out twice and the data 633 in the figure represent the mean of each mouse type (strain / sex) of both experiments. Statistical 634 tests compared B₂R antagonist -treated versus untreated groups.

B) Cytotoxicity assay determining LDH in supernatants from SARS-CoV-2-infected NHBEs
from 12 donors that were treated with/without 1 nM B₂R antagonist after 6 hours of infection
for another 24 hours. C) Quantification of infectious particles in the supernatants from SARSCoV-2-infected NHBEs from 4 donors that were treated with/without 1 nM B₂R antagonist
after 6 hours of infection for another 24 hours. Supernatants were titrated on Vero E6 cells and

plaque assay was quantified 24 hours later. Results are depicted as plaque forming units (PFU)
per milliliter. For Figures 2B-C, statistical tests compared B₂R antagonist-treated versus
untreated samples.

643 D) Relative quantification of total SARS-CoV-2 RNA (viral genome and transcripts, which all 644 contain the N1 sequence region) and G) genomic SARS-CoV-2 RNA (containing the *RdRP* gene) normalized to housekeeping gene index of human ACTB, HPRT, 18S in NHBEs from 8 645 646 independent donors that were infected with SARS-CoV-2 for 6 hours and then treated with 647 increasing doses of the B₂R antagonist icatibant repeatedly every 24 hours for a total of 96 648 hours. In cells treated with E) 100 nM and F) 1000 nM icatibant for 48 hours and with H) 100 649 nM and I) 1000 nM icatibant for 72 hours, total SARS-CoV-2 RNA and genomic SARS-CoV-650 2 RNA were significantly reduced. Red indicates SARS-CoV-2 infection; blue indicates B₂R 651 antagonist treatment. PRE indicates pre-treatment; POST indicates post-treatment. In Fig.2D-652 I, results are depicted as mean \pm s.e.m. and statistical tests compared each dose of icatibant with 653 0 nM icatibant. Statistically significant differences were depicted as p-values *P<0.05, 654 **P<0.01, and ***P<0.001. ns indicates non-significant. + infected / treated; - indicates not 655 infected / not treated.

656

Figure 3. B₂R antagonism exhibits a protective and suppressive effect on gene expression profile of airway epithelial cells.

A) Volcano plots showing global gene expression changes induced by either treatment with B₂R antagonist or hydrocortisone (HC). Red indicates significantly upregulated entities; blue indicates significantly downregulated entities. Gene expression analysis of pre-treated NHBEs after 24 hours of SARS-CoV-2 infection. B) Heat map of gene expression analysis of genes involved in the epithelial antiviral response, analysis of the effects of SARS-CoV-2 infection. Only entities with significant changes between SARS-CoV-2 infection and medium are shown (gene expression fold change $FC \ge 1.5$ with P<0.05). C) Heat map of gene expression analysis

666 of genes involved in the acute phase response are depicted. All entities are shown. Asterisks 667 indicate significantly regulated genes (P<0.05) in SARS-CoV-2 compared to medium. D) Heat 668 map of gene expression analysis of known and potential virus entry receptors are depicted. All 669 entities are shown. Color code indicates Log2-fold change from low (blue) through 0 (white) 670 to high (red). Asterisks indicate significantly regulated genes (P<0.05) in SARS-CoV-2-671 infected NHBEs compared to medium. Duplicate gene names indicate the presence of two or 672 more isoforms of the same gene in the analysis. E) Analysis of *TMPRSS2* gene expression by 673 qPCR after 24 hours of pre-treatment with/without 10 μM hydrocortisone (HC) followed by 24 674 hours of SARS-CoV-2 inoculation. Red indicates SARS-CoV-2 infection; yellow indicates pre-675 treatment with hydrocortisone (HC). Statistical tests compared SARS-CoV-2-infected versus 676 uninfected samples or B₂R antagonist-treated versus untreated samples. 677 F) Quantification of infectious particles in the supernatants of SARS-CoV-2-infected NHBEs

from 10 donors that were pre-treated with/without 10 µM hydrocortisone (HC) for 24 hours.
Supernatants were titrated on Vero E6 cells. The plaque assay was quantified 24 hours later.
Results are depicted as plaque forming units (PFU) per milliliter.

681

Figure 4. B₂R antagonism exhibits a protective and suppressive effect on gene expression profile of airway epithelial cells.

684 GO term enrichment analysis, which results from the string network analysis of significant 685 DEGs from the gene expression analysis comparing infected NHBE pretreated with B₂R 686 antagonist with untreated infected NHBE (SARS-CoV-2 + B2R antagonist versus SARS-CoV-687 2). Depicted are enrichment of A) GO-term GO:0007186 "G protein-coupled receptor signaling 688 pathway" and B) GO-term GO:0006811 "Ion transport". Genes that were significantly 689 upregulated in the comparison SARS-CoV-2 versus medium are highlighted in red. C) Venn 690 diagram showing the cut set of upregulated membrane-bound cell surface receptors in SARS-691 CoV-2 versus medium and of downregulated DEGs in SARS-CoV-2 + icatibant versus SARS-

692	CoV-2 (FC \ge 1.5; P \le 0.05). D) Heat map of gene expression analysis of the 35 membrane-bound
693	cell surface receptors defined in cut set from Fig.4C, all upregulated upon SARS-CoV-2
694	infection and downregulated upon pre-treatment with B2R antagonist are depicted. Only entities
695	with significant changes between SARS-CoV-2 infection and medium (up) and between SARS-
696	CoV-2 + B ₂ R antagonist and SARS-CoV-2 (down) are shown (gene expression fold change
697	$FC \ge 1.5$ with P<0.05). Color code indicates Log2-fold change from low (blue) through 0 (white)
698	to high (red). Duplicate gene names indicate the abundance of two or more isoforms of the same
699	gene in the analysis.

702 Table 1. Demographic data of patient cohort

Parameter	Negative (n = 7)	Positive acute (n = 4)	p-value
Age (years)*	35.86 ± 3.86	37.50 ± 8.78	n.s.
Sex (m/f)	2/5	1/3	
IgM (ng/mL)	1.32 ± 0.28	4.34 ± 2.81	n.s.
IgG (ng/mL)	0.48 ± 0.08	67.08 ± 19.51	0.0061

703 704 negative: tested negative in SARS-CoV-2 qPCR; positive acute: tested positive in SARS-CoV-2 qPCR; IgM:

immunoglobulin M; IgG: immunoglobulin G; values are depicted as mean ± s.e.m.; n.s. not significant

705 *at informed consent procedure and inclusion into study



B - Cytotoxicity

A - Mouse lung: ACE2 protein levels treatment post airway inflammation









Treatment post-infection:

D - total viral RNA

E - total viral RNA 48h

1.2

1.0

0.8

0.6

0.4

0.2

0.0

total SARS-CoV-2 RNA

F - total viral RNA 72h



G - genomic viral RNA



i.

nM B_oR-ant

 $IC_{50} = 92.93$

0.1

ò











FIGURE deprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

A - DEGs: B₂R-ant effect vs HC effect



C - Acute-phase response



D - Entry Receptors





E - TMPRSS2 mRNA HC treatment pre-infection



F - Plaque assay HC treatment pre-infection



FIGURE Areprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in membrane-bound deliver allowed without permission. All rights reserved. No reuse allowed without permission. SARS-CoV-2 + B₂R-ant vs SARS-CoV-2



C - Counter-regulation of SARS-CoV-2-induced DEGs by $\mathrm{B_2R}$ antagonist





D - Membrane-bound cell surface receptors

